A new saliva-based assay rapidly and accurately assesses flavivirus immunity by measuring multiple antibody classes in saliva. The test can distinguish between individuals with polytypic dengue virus immunity and those who have previously experienced both dengue virus and Zika virus infections.
A University of Minnesota-led team discovered a highly potent small molecule, MWAC-3634, that blocks Ebola virus entry by stabilizing the virus's entry protein. The compound shows strong protection when given orally in a preclinical model.
Two studies on the 2026 Bundibugyo virus outbreak highlight new approaches to rapid diagnostics and vaccine preparedness. Diagnostic tests can be evaluated rapidly during an outbreak, and the 2026 virus may offer some cross-protection with existing Ebola vaccines.
The Osaka Metropolitan University, K.K. DNAFORM, and INRB have developed a portable rapid diagnostic system for Ebola virus disease caused by Bundibugyo virus. The system utilizes the GenPad POCT platform and can be used near outbreak sites without power infrastructure.
JMIR Publications invites submissions on the 2026 Ebola disease public health emergency of international concern, focusing on response strategies, risk communication, and surveillance. The World Health Organization has declared a public health emergency due to population mobility and ongoing uncertainty in the Democratic Republic of th...
A growing DRC Ebola outbreak has confirmed transmission in Uganda, and experts estimate a 70% chance of it spreading to South Sudan. The virus is potentially on course to reach South Sudan due to busy border crossings.
Hantavirus and Ebola virus disease are two deadly infectious diseases that require rigorous infection and prevention control (IPAC) practices. Both diseases present with similar early symptoms and can be treated effectively with proper precautions.
A study analyzing all known Ebola disease cases outside Africa since 1976 found a low overall risk of exportation. Local, community-based case management and infection prevention at the outbreak source are considered key strategies to mitigate transmission risk.
Researchers found that Ebola virus can persist in cerebral organoids for up to 120 days, infecting various cell types, including neurons and astrocytes. The virus can trigger local inflammation and lead to disease relapses in survivors, highlighting the need for improved treatments.
Elsevier has launched its Ebola Information Center, providing free access to critical clinical and research information to support the global response to the outbreak. The center combines evidence-based clinical guidance, peer-reviewed research, and AI-assisted tools to aid in rapid evidence discovery and response coordination.
The Global Virus Network will host an international media briefing on the ongoing Ebola outbreak in the Democratic Republic of Congo. Frontline experts from the DRC, WHO, Africa CDC, and leading Ebola researchers will discuss outbreak response, diagnostics, vaccines, and therapeutics.
A new predictive model developed at Washington State University can identify the reservoirs of emerging zoonotic viruses and dangerous pathogens like Ebola. The model uses serological data and seasonal biological patterns to narrow down when viruses are most likely to be found in wildlife.
Researchers at Southwest Research Institute (SwRI) and Texas Biomedical have identified nearly two dozen antiviral compounds that could potentially treat Bundibugyo Ebolavirus. The project utilizes AI and machine learning tools to quickly identify drug candidates, with Texas Biomed set to screen the compounds in the coming weeks.
The Global Virus Network calls for greater financial, logistical and research support for the local response to the Bundibugjo Ebola virus outbreak in Africa. The spread of this virus underscores the global threat posed by viral outbreaks, with no readily available diagnostics or treatments.
Researchers at Wake Forest Institute for Regenerative Medicine have identified a unique gene pattern specific to Ebola, allowing doctors to distinguish it from other infections. This discovery has the potential to improve diagnostic tests and save lives in outbreak settings.
Researchers at Kyoto University have detailed the structure of Borna disease virus 1's nucleoprotein-RNA complex, revealing a distinct binding mode and incremental model of viral replication. The study provides a molecular framework for targeting viral RNA synthesis and assembly.
The study provides new insight into how the tick-borne virus replicates and matures, with detailed three-dimensional images revealing the virus's interior. The researchers also observed how a small genetic difference between variants affects maturation speeds, paving the way for future treatments against TBE.
Researchers at Penn State found that Ebola outbreaks are influenced by environmental and human factors, including weather patterns, vegetation health, and human movement. A strong positive correlation was found between the total length of roads and rivers in outbreak locations and the number of Ebola cases reported early in each outbreak.
Researchers discovered Marburg virus enters human cells up to 300 times more efficiently than Ebola, thanks to its unique entry protein. A nanobody has been identified to block its attachment to the receptor, providing a potential therapeutic strategy.
A recent Nipah virus outbreak in India highlights the importance of surveillance and global collaboration in detecting emerging infectious threats. The Global Virus Network emphasizes that while sporadic cases are not unprecedented, sustained public-good investment is necessary to develop vaccines and treatments.
A new nanoparticle vaccine strategy has been developed to protect against multiple filovirus strains, including Ebola. The vaccine candidates display filovirus surface proteins on engineered nanoparticles, helping the immune system recognize and respond to the virus.
Researchers at Mass General Brigham developed a modified herpes simplex virus that stimulates the immune system to attack glioblastoma cells, increasing T-cell and natural killer cell responses. The virus, engineered to recognize markers found on glioblastoma cells, also increases overall survival in preclinical models.
New research suggests a common childhood virus can trigger DNA damage leading to bladder cancer. Laboratory studies using human tissue samples found that the virus's antiviral defences cause collateral damage in cells' own DNA.
A WSU study found that over half of Sudan Ebola survivors suffer from debilitating health problems two years post-infection. The virus can persist in semen and breast milk for up to six months after recovery, raising concerns about transmission risks.
Researchers from University of Zurich and Basel decode historical specimen to understand how 1918-1920 influenza pandemic evolved in Europe. The Swiss genome reveals three key adaptations that made the virus more resistant to human immunity and more infectious.
The African Swine Fever virus has been in Europe since 2007, not recently introduced. Travel patterns within Europe are largely responsible for its current spread. The study found that the virus shares a common ancestor with those in Africa, but with no evidence of recent exchange.
A study reveals claudin-11 facilitates depolymerization of F-actin, promoting maturation of influenza virus-containing clathrin-coated vehicles. Claudin-11 silencing leads to increased survival rate in infected mice.
Researchers at Kyoto University have captured the first high-resolution structure of Ebola's nucleocapsid using single-particle cryo-electron microscopy. This visualization reveals sophisticated interactions between structural components, including VP24 and NP proteins, which govern virus assembly, RNA synthesis, and transport.
Researchers from La Jolla Institute for Immunology and UC San Diego discover Zika virus blocks dendritic cells' ability to alert T cells, while dengue virus stimulates pro-inflammatory cytokines, leading to a stronger but uncontrolled immune response. Understanding these differences is key to developing life-saving vaccines.
Scientists have identified a new target to prevent cold sores by understanding how the herpes virus triggers its own immune response. The discovery has important implications for genital herpes caused by the same virus, with potential treatments in development.
A new study led by La Jolla Institute for Immunology scientists found that children who experience multiple dengue virus infections develop protective T cells, which help fight the virus. These T cells appear to be key to dengue virus immunity and may inform the development of a vaccine that prompts a similar response.
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
The CSIC-UNESPA scientific expedition has confirmed the presence of the highly pathogenic avian influenza virus (HPAI H5N1) in all species analyzed on six islands north of the Antarctic Peninsula. The virus was detected in dead and live animals, including penguins, seals, and birds.
A new retrospective study found that nearly half of patients with fever of unknown origin in sub-Saharan Africa had a detectable pathogen, including bacterial strains and hemorrhagic fever viruses. The study highlights the need for strengthened laboratory capacity to improve diagnosis and treatment.
Influenza A virus particles can change shape from spheres to larger filaments to favor infection efficiency, according to a new NIH study. The researchers developed a method to observe real-time structure formation and found that filament shape requires more energy, helping the virus evade immune responses.
A recent study published in Communications Biology reveals that the Sudan virus binds to human cells through a specific protein called NPC1, which enables it to attach with nine times greater affinity than Ebola. This discovery may contribute to the high fatality rate of the Sudan virus.
The COMBINE project focuses on the critical virus-cell binding step, aiming to identify key factors and potential therapeutic targets involved early in viral infections. The team will use a combination of pioneering approaches to develop novel inhibitors and vaccine candidates.
Researchers at Harvard Medical School and Boston University have mapped the structure of the Nipah virus's polymerase complex, a key piece of its machinery. This discovery provides a detailed understanding of how the pathogen multiplies inside hosts and could inform the design of treatments.
Researchers developed a new model to identify potential hosts of ebolaviruses, focusing on bat species with strong NPC1 protein binding and previous outbreak locations. The study uses large-scale binding assays and machine learning to guide future surveillance efforts.
Researchers at Uppsala University found that Semliki Forest virus penetrates the central nervous system by entering the cerebrospinal fluid and binding to VLDLR before penetrating deeper into the brain. This finding could be used to develop the virus as an agent for treating brain cancer.
Researchers at the University of Minnesota have developed two new nanobody inhibitors for Ebola: Nanosota-EB1 and Nanosota-EB2. These tiny antibodies target different parts of the virus, preventing it from attaching to cells and spreading. Lab tests show promising results, achieving a 100% survival rate in Ebola-infected mice.
Researchers at the University of Iowa Health Care have identified a cellular route used by Ebola virus to traverse skin layers and emerge onto the skin surface. The study suggests that the skin's surface may be one route of person-to-person transmission, with human skin specimens actively supporting EBOV infection.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
Researchers found a bovine H5N1 virus isolated from an infected worker to be transmissible and lethal in mice and ferrets, with limited efficiency. The virus is susceptible to certain antiviral drugs, including favipiravir and baloxavir marboxil.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
A new study by Karolinska Institutet researchers has identified the protein on cell surfaces that the Crimean-Congo hemorrhagic fever virus uses to enter human cells. This discovery is crucial in developing effective treatments and vaccines for the deadly disease, which can cause up to 40% mortality rate.
Texas Children's Hospital and Baylor College of Medicine researchers have created a toolkit of transgenic flies expressing all ten Zika virus proteins. The study found that these protein expressions induced diverse effects on the developing nervous system, including lethality, reduced brain size, and functional defects. This new experi...
Scientists are studying the replication mechanism of Zika virus and its ability to transmit from an infected mother to her unborn child. They aim to understand how the virus creates connections called tunneling nanotubes that allow it to replicate and infect cells.
Researchers found that ferrets infected with influenza or respiratory syncytial virus were more susceptible to lethal pneumonia when later infected with a measles-like virus. Experimental treatment with GHP-88309 prevented this outcome, suggesting a potential therapeutic option.
A European study links agricultural activities with West Nile virus emergence and spread, as well as urbanization and migratory bird patterns. The study highlights the need for enhanced surveillance in Central Europe.
Researchers found that Ebola virus creates tunneling nanotubes to transfer particles to new cells, evading treatments and spreading infection. The discovery suggests a new route of dissemination for the deadly virus.
A new vaccine patch has delivered an effective immune response to Zika virus in mice, providing rapid protection against the disease. The patch, which uses a high-density microarray platform, targets a specific protein crucial to the virus's survival and evokes T-cell responses up to 270% higher than traditional vaccines.
A study by Lund University researchers mapped the effects of temperature on a virus particle's genetic material, revealing its rapid injection into cells at elevated temperatures. The findings suggest that higher body temperature may increase the risk of infection spread.
Researchers have developed a lab-grown human skin model that effectively replicates mpox virus infections, providing insights into the virus's mechanisms of attack on skin cells. The study reveals how the virus causes disease and identifies potential therapeutic targets, including an antiviral drug called tecovirimat.
Chikungunya virus has found a way to evade the immune system by hijacking host cells' cytoskeleton, allowing it to spread directly from cell to cell. This discovery could lead to the development of effective vaccines or treatments for this debilitating mosquito-borne disease.
Researchers at La Jolla Institute for Immunology have discovered the inner workings of Ebola virus replication inside host cells, revealing 'viral factories' that form clusters of viral proteins and genomes. These microscopic structures are formed in host cells and play a crucial role in the virus's life cycle.
Researchers from the University of Copenhagen have solved the mystery of how the Hepatitis C virus evades the human immune system. The virus uses a molecule called FAD as a 'mask', cloaking itself in a form that is already present in cells, making it invisible to the immune system.
Researchers have developed an experimental decoy that provides long-term protection from SARS-CoV-2 infection in mice by binding to the virus's spike protein. The treatment was found to be highly effective, with 100% protection against lethal doses of the virus and a significant reduction in viral load.
Scientists at Scripps Research have determined the structure of the critical protein complex that lets Lassa virus infect human cells, identifying new antibodies and vaccine targets. The research also found a high level of conservation across different lineages of the virus, paving the way for more effective vaccines and treatments.
Heidelberg researchers have identified key proteins that can prevent the formation of fusion pores, allowing viruses like influenza A and Ebola to be trapped in a lipid membrane. This breakthrough could lead to new approaches for preventing infections with these highly infectious viruses.